London-based biotech company Engitix has raised €21 million ($25 million) in a Series A extension to advance its work on therapies targeting the extracellular matrix (ECM) in cancer and fibrotic diseases.
The financing was provided by Netherton Investments, investing on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management.
Expanding an ECM-driven therapeutic strategy
Engitix focuses on understanding how the extracellular matrix shapes disease progression and using that insight to design targeted treatments. According to CEO and co-founder Giuseppe Mazza, the new funding strengthens the company’s ability to translate its ECM expertise into a broader pipeline of therapeutic candidates across oncology and fibrosis.
The company’s approach combines large-scale ECM datasets with translational biology and drug development, enabling the identification of disease-specific targets within tissue microenvironments. This strategy is designed to generate differentiated therapies with the potential to deliver more meaningful clinical outcomes.
Advertisement
Positioned within a strong European biotech funding cycle
The Series A extension comes amid sustained investment activity across European biotech in 2025, particularly in oncology and fibrosis. Engitix’s round aligns with a broader wave of mid- and later-stage financings across the region, reflecting continued investor confidence in advanced therapeutic platforms addressing high-unmet-need indications.
Partnerships supporting development
Founded in 2016, Engitix has built strategic collaborations to support its pipeline. The company maintains a drug discovery partnership with Dompé farmaceutici and works with Takeda on programmes focused on advanced fibrotic liver diseases.
Mike Platt commented that Engitix operates at a compelling intersection of data, biology, and drug development, adding that the company’s strategy in fibrosis and solid tumours positions it well for continued progress.
Use of proceeds and next steps
The newly secured capital will be used to accelerate preclinical development across Engitix’s proprietary ECM-targeted programmes in solid tumours and fibrosis. Funding will also support further expansion and application of the company’s platform, which is built on one of the largest proprietary ECM datasets in these disease areas.
About Engitix Therapeutics
Engitix Therapeutics is a UK-based biotech company focused on developing new treatments for cancer and fibrotic diseases by targeting the human extracellular matrix. Through its proprietary ECM platform and translational biology capabilities, the company is building a pipeline of therapies designed to act directly within diseased tissue environments, with the aim of improving outcomes for patients facing life-threatening conditions.
